Keyphrases
Adequate Dose
8%
AIDS/HIV
11%
Amphotericin B
10%
Antibiotics
10%
Cardiovascular Risk
10%
Clinical Features
9%
Clinical Pharmacist
45%
Clinical Pharmacy
16%
Community Pharmacy
10%
Coronavirus Disease (COVID)
10%
COVID-19
19%
COVID-19 Guidelines
8%
Crystal Engineering
8%
Crystalline Formulation
8%
Engineering Approach
8%
Fungal Infection
17%
Healthcare Professionals
10%
Heath Risk
8%
Homozygous Familial Hypercholesterolemia (HoFH)
17%
Hypercholesterolemia
13%
Invasive Fungal Infection
10%
Liraglutide
8%
Low-income Countries
10%
Monoclonal Antibody
9%
Mycoses
8%
Nanoengineering
8%
Non-pharmacological
8%
Obesity Management
13%
Obesity Treatment
13%
Patient Care
14%
Patient Demographics
13%
Pharmaceutical Care
10%
Pharmacist
55%
Pharmacist Role
20%
Post-pandemic
8%
Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9)
9%
Public Hospitals
14%
Quality of Life
11%
Rest of the World
13%
Risk Factors
10%
Sinusitis
10%
Smokers
13%
Smoking Cessation
26%
Smoking Prevalence
22%
Social Media
10%
South Africa
100%
Tobacco Control Programs
13%
Treatment Options
11%
Tuberculosis Incidence
8%
Weight Loss
13%
Pharmacology, Toxicology and Pharmaceutical Science
Acetylsalicylic Acid
8%
Adverse Drug Reaction
8%
Adverse Event
5%
Amphotericin B
5%
Antibiotic Agent
10%
Antibiotics
8%
Antifungal Agent
8%
Cardiovascular Disease
7%
Cardiovascular Risk
8%
Cholera
8%
Chronic Disease
13%
Clinical Feature
9%
Codeine
8%
Colchicine
8%
Community Pharmacy
10%
Coronavirinae
14%
Cross-Sectional Study
9%
Crystal Engineering
8%
Disease
26%
Epidemic
14%
Familial Hypercholesterolemia
17%
Genetic Predisposition
5%
HIV
12%
Hospital Pharmacy
8%
Hydroxychloroquine
8%
Hypercholesterolemia
13%
Infection
8%
Ivermectin
8%
Liraglutide
8%
Malignant Neoplasm
12%
Monoclonal Antibody
9%
Mycosis
17%
Neoplasm
8%
Obesity
17%
Pandemic
8%
Pharmaceutical Care
17%
Pharmacotherapy
6%
Polypharmacy
8%
Proprotein Convertase 9
12%
Rhinosinusitis
8%
Seizure
8%
Sinusitis
11%
Statin (Protein)
11%
Symptom
15%
Systemic Mycosis
6%
Vitamin D
8%
Medicine and Dentistry
Antifungal Agent
8%
Asthma
8%
Cardiovascular Risk
8%
Cholera
8%
Clinical Feature
5%
Colchicine
8%
COVID-19
15%
Disease
10%
Drug Therapy
11%
Familial Hypercholesterolemia
8%
Human Immunodeficiency Virus
5%
Hydroxychloroquine
8%
Hypercholesterolemia
5%
Inflammatory Disorder
6%
Ivermectin
8%
Medicine
7%
Monoclonal Antibody
5%
Mycosis
8%
Nicotine Withdrawal
26%
Pandemic
8%
Patient Care
8%
Prevalence
6%
Proprotein Convertase 9
8%
Public Health
8%
Rhinosinusitis
8%
Sinusitis
10%
Smoking
20%
Social Media
10%
Supplementation
8%
Vitamin D
8%
